Immune checkpoint inhibitors and prostate cancer: a new frontier?

  • Alessandra Modena Medical Oncology, University-Hospital of Verona, Verona, Italy.
  • Chiara Ciccarese Medical Oncology, University-Hospital of Verona, Verona, Italy.
  • Roberto Iacovelli Medical Oncology, University-Hospital of Verona, Verona, Italy.
  • Matteo Brunelli Department of Pathology and Diagnostic, University-Hospital of Verona, Verona, Italy.
  • Rodolfo Montironi Section of Pathological Anatomy, Polytechnic University of Marche Region, School of Medicine, Ancona, Italy.
  • Michelangelo Fiorentino Pathology Service, Addarii Institute of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy.
  • Giampaolo Tortora Medical Oncology, University-Hospital of Verona, Verona, Italy.
  • Francesco Massari | fmassari79@gmail.com Division of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy.

Abstract

Despite recent advances in the treatment of metastatic castrationresistant prostate cancer (mCRPC), agents that provide durable disease control and long-term survival are still needed. It is a fact that a tumor-induced immunosuppressive status (mediated by aberrant activation of inhibitory immune checkpoint pathways as a mechanism to evade host immune surveillance) plays a crucial role in the pathogenesis of cancer, including prostate cancer (PC), making CRPC patients suitable candidates for immunotherapy. Therefore, growing interest of anticancer research aims at blocking immune checkpoints (mainly targeting CTLA-4 and PD1/PD-L1 pathways) to restore and enhance cellular-mediated antitumor immunity and achieve durable tumor regression. In this review, we describe the current knowledge regarding the role of immune checkpoints in mediating PC progression, focusing on CTLA-4 and PD1 pathways. We also provide current clinical data available, an update on ongoing trials of immune checkpoint inhibitors in PC. Finally, we discuss the necessity to identify prognostic and predictive biomarkers of immune activity, and we analyze new immune checkpoints with a role as promising targets for PC therapy.

Downloads

Download data is not yet available.
Published
2016-04-15
Section
Reviews
Keywords:
Prostate cancer, immunotherapy, immune checkpoint inhibitors, CTLA-4, PD-1, PD-L1.
Statistics
Abstract views: 3441

PDF: 1497
HTML: 1276
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Modena, A., Ciccarese, C., Iacovelli, R., Brunelli, M., Montironi, R., Fiorentino, M., Tortora, G., & Massari, F. (2016). Immune checkpoint inhibitors and prostate cancer: a new frontier?. Oncology Reviews, 10(1). https://doi.org/10.4081/oncol.2016.293